REGULATORY INFORMATION

Home  |  Consumers  |  Health Professionals  |  Regulatory  |  Other  |  Hot Topics  |  Search

• Guidelines & Codes
• Forms
• Fees
• Gazette Notices
• Data Sheets and CMI
• MAAC Dates
• Pharmacovigilance
• Classification of Medicines
• Unapproved Medicines
• Web Assisted Notification of Devices (WAND)
• Medical Devices
• Complementary Medicines
• Licensed Manufacturing Sites
• GMP Certified Testing Labs
• Advertising
• Consultants
• Investigations
• Influenza vaccine formulation
• Product/Application Search
• Contact DART email

Influenza Vaccine Formulation

The recommended influenza vaccine composition for New Zealand in 2008 is:

• A(H1N1): an A/Solomon Islands/3/2006 (H1N1)-like strain (15 μg HA per dose)
• A(H3N2): an A/Brisbane/10/2007 (H3N2)-like strain (15 μg HA per dose)
• B: a B/Florida/4/2006-like strain (15 μg HA per dose)

The following viruses are suitable vaccine strains:

• A/Solomon Islands/3/2006 (IVR-145)
• A/Brisbane/10/2007 (IVR-147)
• B/Florida/4/2006 or B/Brisbane/3/2007

This recommendation is based on the outcome of:

• The meeting of the Australian Influenza Vaccine Committee, with a New Zealand representative, to consult on the influenza vaccine composition for 2008 (held in Canberra on 3rd October 2007),
• Information on international surveillance by the World Health Organisation (WHO),
• Recent data from Australia, New Zealand and South Africa on epidemiology and strain characterisation, and
• The recommendations of the WHO annual consultation on the composition of influenza vaccine for the Southern Hemisphere (held in Geneva in September 2007).